# Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

> **NCT02876107** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Breast Carcinoma
- Breast Lump
- Edema
- Erythema
- Estrogen Receptor Negative
- HER2/Neu Negative
- Inflammatory Breast Carcinoma
- Invasive Breast Carcinoma
- Peau d'Orange
- Progesterone Receptor Negative
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Panitumumab

## Key facts

- **NCT ID:** NCT02876107
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-06
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876107, "Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02876107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*